DiaSolution
DiaSolution has designed an innovative probiotic to alleviate symptoms of diabetes as an all-natural product with protective effects on pancreatic, liver and kidney cells, contributing to improved quality of patients’ life without any side effects. Results have already been proven in preclinical animal studies, and further clinical study is scheduled in cooperation with the Medical Faculty in Belgrade.
The new probiotic is expected to enter the domestic market by the end of 2022, and then the global market through a strategic partnership with leading partners from the pharmaceutical industry in 2–3 years. The primary market is the global market for functional foods, especially value-added foods for specific diets, particularly for diabetes.
Representatives

Damjan Damnjanović, CMO

Milica Živković, CEO
